Mathieu Losguardi is the CEO of Temisis Therapeutics, an emerging biotech company focusing on the discovery and development of novel oral treatments for immune-inflammatory indications, of which psoriasis and ulcerative colitis. Prior to joining Temisis, Mathieu has had more than 10 years of experience as an investment banker, notably at Evercore and Socgen, where he used to manage complex M&A, IPO and licensing deals in the Healthcare and Life Sciences sectors.